TWI681770B - 加瑪-羥丁酸鹽組合物及其於治療病症之用途 - Google Patents

加瑪-羥丁酸鹽組合物及其於治療病症之用途 Download PDF

Info

Publication number
TWI681770B
TWI681770B TW106143923A TW106143923A TWI681770B TW I681770 B TWI681770 B TW I681770B TW 106143923 A TW106143923 A TW 106143923A TW 106143923 A TW106143923 A TW 106143923A TW I681770 B TWI681770 B TW I681770B
Authority
TW
Taiwan
Prior art keywords
ghb
salt
pharmaceutical composition
certain embodiments
mixture
Prior art date
Application number
TW106143923A
Other languages
English (en)
Chinese (zh)
Other versions
TW201831174A (zh
Inventor
P 歐芬克拉克
德嘉丁麥克
Original Assignee
愛爾蘭商爵士製藥愛爾蘭有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI681770(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 愛爾蘭商爵士製藥愛爾蘭有限責任公司 filed Critical 愛爾蘭商爵士製藥愛爾蘭有限責任公司
Publication of TW201831174A publication Critical patent/TW201831174A/zh
Application granted granted Critical
Publication of TWI681770B publication Critical patent/TWI681770B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW106143923A 2012-12-14 2013-12-13 加瑪-羥丁酸鹽組合物及其於治療病症之用途 TWI681770B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737695P 2012-12-14 2012-12-14
US61/737,695 2012-12-14

Publications (2)

Publication Number Publication Date
TW201831174A TW201831174A (zh) 2018-09-01
TWI681770B true TWI681770B (zh) 2020-01-11

Family

ID=49596603

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106143923A TWI681770B (zh) 2012-12-14 2013-12-13 加瑪-羥丁酸鹽組合物及其於治療病症之用途
TW102146274A TWI639425B (zh) 2012-12-14 2013-12-13 加瑪－羥丁酸鹽組合物及其於治療病症之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW102146274A TWI639425B (zh) 2012-12-14 2013-12-13 加瑪－羥丁酸鹽組合物及其於治療病症之用途

Country Status (24)

Country Link
US (9) US8591922B1 (cg-RX-API-DMAC7.html)
EP (3) EP2931268B1 (cg-RX-API-DMAC7.html)
JP (1) JP6215347B2 (cg-RX-API-DMAC7.html)
KR (1) KR102180343B1 (cg-RX-API-DMAC7.html)
CN (1) CN105025892B (cg-RX-API-DMAC7.html)
AU (1) AU2013359114B2 (cg-RX-API-DMAC7.html)
CA (1) CA2894876C (cg-RX-API-DMAC7.html)
CY (2) CY1119918T1 (cg-RX-API-DMAC7.html)
DK (2) DK3335709T3 (cg-RX-API-DMAC7.html)
ES (2) ES2660056T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201685T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051060T2 (cg-RX-API-DMAC7.html)
IL (1) IL239355A (cg-RX-API-DMAC7.html)
IN (1) IN342829B (cg-RX-API-DMAC7.html)
LT (1) LT3335709T (cg-RX-API-DMAC7.html)
MX (1) MX366681B (cg-RX-API-DMAC7.html)
NO (1) NO3027826T3 (cg-RX-API-DMAC7.html)
PL (1) PL2931268T3 (cg-RX-API-DMAC7.html)
PT (2) PT3335709T (cg-RX-API-DMAC7.html)
SG (1) SG11201504637TA (cg-RX-API-DMAC7.html)
SI (1) SI3335709T1 (cg-RX-API-DMAC7.html)
TR (1) TR201802271T4 (cg-RX-API-DMAC7.html)
TW (2) TWI681770B (cg-RX-API-DMAC7.html)
WO (1) WO2014093791A1 (cg-RX-API-DMAC7.html)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012024019B1 (pt) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA3207643A1 (en) 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
IL275444B2 (en) 2017-12-18 2025-01-01 Tris Pharma Inc Modified release drug powder formulation containing gastric-retaining raft-forming systems with pulsed drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
US20210186907A1 (en) * 2019-12-24 2021-06-24 Jazz Pharmaceuticals Ireland Limited Ghb dosing
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR102436227B1 (ko) * 2020-05-29 2022-08-24 주식회사 케이티앤지 기능성 물질이 코팅된 흡연물품용 팁페이퍼 및 상기 팁페이퍼의 코팅 방법
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) * 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US20230404950A1 (en) 2020-10-08 2023-12-21 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
TW202228666A (zh) 2020-10-16 2022-08-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 使用ghb之治療方法
EP4308086B1 (en) 2021-03-19 2025-10-15 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CA3209150A1 (en) * 2021-03-20 2022-09-29 Jayprakash Ajitsingh PARIHAR A process for the preparation of mixed oxybate salts and polymorphs thereof
US11877992B1 (en) 2021-06-07 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of learning disorders
US11877993B1 (en) 2021-06-23 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of psychological disorders
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
CN118974001A (zh) 2022-04-21 2024-11-15 泽夫拉治疗公司 γ-羟基丁酸酯递送化合物以及制备和使用它们的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113366A1 (en) * 2000-11-27 2005-05-26 Jean-Jacques Bourguignon Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses
US20120202880A1 (en) * 1998-12-23 2012-08-09 Jazz Pharmaceuticals, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US4374441A (en) 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
IT1283782B1 (it) 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
US6495598B1 (en) 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
CA2423358C (en) 2000-09-22 2011-05-17 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8410304B2 (en) 2009-04-15 2013-04-02 Norac Pharma Process for preparing gamma-hydroxybutyrate
MX340591B (es) * 2010-05-04 2016-07-15 Jazz Pharmaceuticals Inc * Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202880A1 (en) * 1998-12-23 2012-08-09 Jazz Pharmaceuticals, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20050113366A1 (en) * 2000-11-27 2005-05-26 Jean-Jacques Bourguignon Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12115143B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115144B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263151B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en) 2016-07-22 2024-10-08 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115145B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115142B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263150B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12128021B1 (en) 2016-07-22 2024-10-29 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12138239B2 (en) 2016-07-22 2024-11-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12144793B2 (en) 2016-07-22 2024-11-19 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12257223B2 (en) 2016-07-22 2025-03-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12239625B2 (en) 2016-07-22 2025-03-04 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186298B2 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226389B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226388B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US12226377B2 (en) 2019-03-01 2025-02-18 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167992B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167991B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12303478B2 (en) 2019-03-01 2025-05-20 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12295926B1 (en) 2022-02-07 2025-05-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Also Published As

Publication number Publication date
NO3027826T3 (cg-RX-API-DMAC7.html) 2017-12-16
IL239355A0 (en) 2015-07-30
US20140171505A1 (en) 2014-06-19
CA2894876C (en) 2017-08-29
US20140171506A1 (en) 2014-06-19
EP3799867A1 (en) 2021-04-07
US20200338029A1 (en) 2020-10-29
TWI639425B (zh) 2018-11-01
IL239355A (en) 2017-05-29
KR20150100737A (ko) 2015-09-02
SG11201504637TA (en) 2015-07-30
MX2015007531A (es) 2016-03-11
PT2931268T (pt) 2018-02-27
LT3335709T (lt) 2020-11-25
HUE051060T2 (hu) 2021-03-01
EP2931268A4 (en) 2016-06-01
US9555017B2 (en) 2017-01-31
AU2013359114A1 (en) 2015-07-02
DK3335709T3 (da) 2020-10-19
PT3335709T (pt) 2020-10-21
TW201831174A (zh) 2018-09-01
MX366681B (es) 2019-07-19
EP3335709A1 (en) 2018-06-20
IN342829B (cg-RX-API-DMAC7.html) 2016-07-01
US8901173B2 (en) 2014-12-02
CY1119918T1 (el) 2018-06-27
US20220000815A1 (en) 2022-01-06
TR201802271T4 (tr) 2018-03-21
AU2013359114B2 (en) 2017-01-19
CA2894876A1 (en) 2014-06-19
US20170209396A1 (en) 2017-07-27
US9132107B2 (en) 2015-09-15
EP2931268B1 (en) 2017-11-22
JP2016503762A (ja) 2016-02-08
ES2660056T3 (es) 2018-03-20
CY1123498T1 (el) 2022-03-24
KR102180343B1 (ko) 2020-11-19
CN105025892A (zh) 2015-11-04
DK2931268T3 (en) 2018-02-26
WO2014093791A1 (en) 2014-06-19
TW201429469A (zh) 2014-08-01
US8591922B1 (en) 2013-11-26
ES2827005T3 (es) 2021-05-19
US11554102B2 (en) 2023-01-17
JP6215347B2 (ja) 2017-10-18
EP3335709B1 (en) 2020-08-12
US10675258B2 (en) 2020-06-09
US10195168B2 (en) 2019-02-05
HK1215181A1 (en) 2016-08-19
CN105025892B (zh) 2018-03-20
PL2931268T3 (pl) 2018-06-29
US20190224149A1 (en) 2019-07-25
EP2931268A1 (en) 2015-10-21
US20160058720A1 (en) 2016-03-03
US20240156759A1 (en) 2024-05-16
HRP20201685T1 (hr) 2020-12-25
BR112015014007A2 (pt) 2017-07-11
SI3335709T1 (sl) 2021-01-29

Similar Documents

Publication Publication Date Title
TWI681770B (zh) 加瑪-羥丁酸鹽組合物及其於治療病症之用途
US20220362185A1 (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
HK1257033A1 (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
HK1257033B (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
HK1215181B (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112015014007B1 (pt) Composição farmacêutica compreendendo sais de sódio, potássio, magnésio e/ou cálcio de gama-hidroxibutirato (ghb), formulação da mesma, bem como seu uso e método de preparação

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees